February 17, 2022 -- PerkinElmer's Sirion Biotech and the Centre for Genomic Regulation (CRG) entered into an agreement to jointly develop new generation adeno-associated virus (AAV) vectors for type 1 and type 2 diabetes gene therapy.
The collaboration combines Sirion's AAV technology platform and expertise in viral vector development and production with CRG's knowledge of genetic regulatory mechanisms. The end goal of the collaboration is to develop AAV vectors that target specific pancreatic cell types and contain payloads that express therapeutic genes under the control of cell-specific regulatory elements. The approach aims to increase the precision, safety, and efficacy of future AAV-based gene therapies for diabetes.
Financial details of the agreement were not disclosed.
CRG is a biomedical research center based in Barcelona, Spain, which has launched five spinoff companies since 2008. It is home to more than 400 interdisciplinary scientists.
PerkinElmer is a global provider of end-to-end solutions that help scientists, researchers, and clinicians better diagnose diseases and discover new and more personalized drugs.